Rise Biopharmaceuticals, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2013-12-02
- Employees
- -
- Market Cap
- -
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Pancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Non-resectable
- Interventions
- Drug: RP72Drug: Gemcitabine
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rise Biopharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04338763
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Chi Mei Hospital, Liouying, Tainan, Taiwan
© Copyright 2025. All Rights Reserved by MedPath